000 05626nam a22004695i 4500
001 978-90-481-8553-5
003 DE-He213
005 20140220084600.0
007 cr nn 008mamaa
008 100623s2010 ne | s |||| 0|eng d
020 _a9789048185535
_9978-90-481-8553-5
024 7 _a10.1007/978-90-481-8553-5
_2doi
050 4 _aRC321-580
072 7 _aPSAN
_2bicssc
072 7 _aMED057000
_2bisacsh
082 0 4 _a612.8
_223
100 1 _aRitsner, Michael S.
_eeditor.
245 1 0 _aBrain Protection in Schizophrenia, Mood and Cognitive Disorders
_h[electronic resource] /
_cedited by Michael S. Ritsner.
264 1 _aDordrecht :
_bSpringer Netherlands :
_bImprint: Springer,
_c2010.
300 _aXVIII, 997p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aNeuroprotective Strategies and Mechanisms -- Brain Protection in Neuropsychiatric Disorders: Past, Present and Future Challenges -- Towards a New Paradigm in Neuroprotection and Neuroplasticity -- What Protects Patients with Schizophrenia from Developing Alzheimer Pathology? -- Assessing In Vivo Neurodegeneration in Schizophrenia Using Magnetic Resonance -- Vulnerability of the Brain to Neuropsychiatric Disorders Resulting from Abnormal Thyroid Hormone or Vitamin D Homeostasis -- Phosphatidylinositol 3-Kinase/Glycogen Synthase Kinase and Mitogen-Activated Protein Kinase Signalling Cascades in Neuronal Cell Survival: What the Neurotrophins Have Taught Us and Implications For Neuropsychiatric Disorders -- One-Compound-Multi-Targets at Amyloid ? Cascade Offered By Bis(7)-Cognitin, a Novel Anti-Alzheimer’s Dimer -- Common Pathways to Neurodegeneration and Co-morbid Depression -- Breakdown of the Blood-Brain Barrier in Stress Alters Cognitive Dysfunction and Induces Brain Pathology: New Perspectives for Neuroprotective Strategies -- Oxidative Stress and Neurodegeneration: An Inevitable Consequence of Aging? Implications for Therapy -- Carbon Nanotubes as Electrical Interfaces with Neurons -- II. Neuroprotective Treatment and Neuromodulation -- Is a Neuroprotective Therapy Suitable for Schizophrenia Patients? -- Recombinant Human Erythropoietin: Novel Approach to Neuroprotection and Neuroregeneration in Schizophrenia -- Neuroprotective Agents in Mood Disorders: Pathophysiological and Therapeutic Implications -- Neuroprotection in Bipolar Depression -- New Antiepileptic Drugs in Neuropsychiatric Disorders – Basic Mechanisms Related to Clinical Efficacy -- The Neuroprotective Efficacy of Vitamins -- Smoking and Mental Disorders: Focus on Neuroprotection -- Inhibition of Glycine Transporter-1 Improves the Functional Outcome of Schizophrenia -- The Role of Oxytocin in Neuropsychiatric Disorders: Concepts and Mechanisms -- Neuromodulation for Neuropsychiatric Disorders: Novel Techniques -Vagus Nerve Stimulation, Transcranial Magnetic Stimulation, Transcranial Direct Current Stimulation, and Deep Brain Stimulation.
520 _aNeuroprotection is a novel perspective for the treatment of disorders that lead to neurodegeneration and disabilities as a result of deterioration of neurons due to apoptosis, oxidative stress, excitotoxicity, and other mechanisms. These mechanisms have implications not only for neurodegenerative disorders, but also for schizophrenia, mood and cognitive disorders. The purpose of this book is to provide an up-to-date overview of basic and clinical studies concerning the neuroprotective approach, mechanisms, and several compounds with neuroprotective properties that may contribute to more efficacious treatment of major mental health disorders. The book is divided into two sections. The first section serves as an introduction and overview of conceptual issues of the neuroprotective approach, and some neurobiological advances. Chapters in this section review definitions, perspectives, and issues that provide a conceptual base for the rest of the book. In addition, this part includes chapters in which the authors present and discuss the findings from basic studies of neurodegenerative mechanisms that are associated with the pathogenesis of major mental health disorders. The second section focuses on findings obtained from clinical trials with neuroprotective compounds, and neuromodulatory techniques. The take-home message is that principles of the neuroprotective approach may be applied to treatment of schizophrenia, mood and cognitive disorders. Contributors to this book are among the most active investigators and clinicians in the field who provide new perspectives not only clarifying ongoing controversies but also propose diverse aspects and new insights to neuroprotection. This book is intended for a broad readership, which includes a broad spectrum of readers including neuroscientists, psychiatrists, neurologists, pharmacologists, clinical psychologists, general practitioners, geriatricians, graduate students, and policy makers in the fields of mental health.
650 0 _aMedicine.
650 0 _aNeurosciences.
650 0 _aPsychiatry.
650 0 _aApplied psychology.
650 1 4 _aBiomedicine.
650 2 4 _aNeurosciences.
650 2 4 _aPsychiatry.
650 2 4 _aBiological Psychology.
650 2 4 _aBiomedicine general.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9789048185528
856 4 0 _uhttp://dx.doi.org/10.1007/978-90-481-8553-5
912 _aZDB-2-SBL
999 _c113484
_d113484